In guideline-recommended drug therapy management, SGLT2 inhibitors with proven benefits are recommended for patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease (Davies et al., 2018). This evidence concerns the gene SLC5A2 and heart failure.